CITY THERAPEUTICS, INC.

• S-1/Aamended IPO prospectusPre-revenueCustomer concentration

  Filed Oct 9

  RNA interference drug developer seeks $165M–$185M gross to fund CITY-FXI trials and early-stage pipeline development

• S-1IPO prospectusAccounting issuePre-revenueCustomer concentration

  Filed Sep 24

  Develops gene-silencing RNA medicines; Biogen collaboration drove FY2025 revenue growth of 388% Y/Y.

Request longer coverage